U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple ...
The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.’s BMY ...
Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking approval of its proposed cancer drug mezigdomide in certain patients with the blood cancer multiple ...
A Faulkner County man is now living cancer-free after a frightening blood cancer diagnosis thanks to new treatment options at ...
The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S ...
Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...
Rahul Banerjee, MD, discusses the most relevant multiple myeloma treatment options presented at the EHA Congress 2026.
MULTIPLE myeloma ICU survival has improved in recent years, with better adjusted one year outcomes despite greater illness ...
Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue their conversation on ...
While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results